



4th Immune Effector Cell Therapies in Multiple Myeloma Workshop

March 24-25, 2023 • Boston, MA

Friday, March 24, 2023

8:00 - 8:15 am

INTRODUCTION AND WELCOME

8:15 - 9:45 am

CLINICAL UPDATES ON CAR T CELLS

CHAIRS: *Sundar Jagannath and Philippe Moreau*

8:15-8:27	Update on ide-cel and cilta-cel in late-line MM	<i>Noopur Raje</i>
8:27-8:39	Real world outcomes with CAR T cells for MM	<i>Doris Hansen</i>
8:39-8:41	Update on other autologous CAR T cells	<i>Matthew Frigault</i>
8:41-8:53	Should we move CAR T cells to early relapse/front line	<i>Tom Martin</i>
8:53-9:45	Discussion	<i>Session faculty + Surbhi Sidana</i>

9:45 - 11:15 am

CLINICAL UPDATES ON BISPECIFIC ABS/TCE'S

CHAIRS: *Saad Usmani and Amrita Krishnan*

9:45-9:57	BCMA bsAbs part 1: Teclistamab and Elranatamab	<i>Alexander Lesokhin</i>
9:57-10:09	BCMA bsAbs part 2: REGN5458, ABBV-383, HPN217, CC-93269	<i>TBC</i>
10:09-10:21	Talquetamab, Cevostamab and other non-BCMA bispecifics	<i>Adam Cohen</i>
10:21-10:33	Treating relapse after bsAb and CART therapies	<i>Samir Parekh</i>
10:33-11:15	Discussion	<i>Session faculty + Simon Harrison</i>

11:15 - 11:30 am

BREAK

11:30 am - 1:00 pm	REAL WORLD CONSIDERATIONS FOR T CELL DIRECTED THERAPIES	
	CHAIRS: <i>Sagar Lonial and Francesca Gay</i>	
11:30-11:42	Managing logistics of commercial CART therapies	<i>Yi Lin</i>
11:42-11:54	How should we sequence BCMA directed therapies	<i>Krina Patel</i>
11:54-12:06	Is there a role for maintenance therapy post-CART?	<i>Alfred Garfall</i>
12:06-12:18	Role of MRD testing after CAR T and bsAb therapy	<i>Bruno Paiva</i>
12:18-1:00	Discussion	<i>Session faculty + Nikhil Munshi, Hermann Einsele</i>

1:00 - 1:45 pm **LUNCH**

1:45 - 3:15 pm	NEXT GENERATION CELL THERAPY APPROACHES	
	CHAIRS: <i>Kenneth Anderson and Maria-Victoria Mateos</i>	
1:45-1:57	Novel CART manufacturing approaches	<i>Adam Sperling</i>
1:57-2:09	Allogeneic CAR T approaches	<i>Sham Mailankody</i>
2:09-2:21	NK-based CAR and bispecific approaches	<i>Jeffrey Miller</i>
2:21-2:33	CAR-macrophage therapy for cancer	<i>Michael Klichinsky</i>
2:33-3:15	Discussion	<i>Session faculty + Salomon Manier</i>

3:15 - 3:30 pm **BREAK**

3:30 - 4:50 pm	MANAGING TOXICITIES OF T CELL DIRECTED THERAPIES	
	CHAIRS: <i>Jesus Berdeja and Ajai Chari</i>	
3:30-3:42	COVID vaccine responses post-BCMA directed treatments	<i>Evangelos Terpos</i>
3:42-3:54	Strategies to mitigate risk of CRS and HLH	<i>Sandy Wong</i>
3:54-4:06	What's new in prevention and management of neurotoxicity?	<i>Bianca Santomaso</i>
4:06-4:50	Discussion	<i>Session faculty + Omar Nadeem</i>

Saturday, March 25, 2023

8:00 - 8:05 am **WELCOME**

8:05 - 8:35 am	PLENARY TALK: MICROBIOME	<i>Marcel van den Brink</i>
----------------	---------------------------------	-----------------------------

8:35 - 10:10 am	DETERMINANTS OF RESPONSE/RESISTANCE PART I CHAIRS: <i>Carlos Fernandez de Larrea and David Avigan</i>	
8:35-8:47	Overview of resistance mechanisms	<i>Niels van de Donk</i>
8:47-8:59	Predicting response to CAR T cells: lessons from CD19 CARTs	<i>Mark Leick</i>
8:59-9:11	Correlates of ide-cel response	<i>Mehmet Samur</i>
9:11-9:23	Correlates of cilta cel response	<i>Enrique Zudaire</i>
9:23-10:10	Discussion	<i>Session faculty + Paola Neri</i>
10:10 - 10:30 am	BREAK	
10:30 am - 12:00 pm	DETERMINANTS OF RESPONSE/RESISTANCE PART II CHAIRS: <i>Joaquin Martinez-Lopez and Maria Themeli</i>	
10:30-10:42	Profiling immune cells in BsAb therapy	<i>Nizar Bahlis</i>
10:42-10:54	Role of antigen loss in resistance	<i>Leo Rasche</i>
10:54-11:06	Role of microenvironment in response/resistance	<i>Madhav Dhodapkar</i>
11:06-11:18	Role of microbiome in resistance/response to CAR T	<i>Matteo Bellone</i>
11:18-12:00	Discussion	<i>Session faculty + Adam Cohen</i>
12:00 - 12:45 pm	LUNCH	
12:45 - 2:15 pm	OVERCOMING RESISTANCE TO T CELL-DIRECTED THERAPIES CHAIRS: <i>Kwee Yong and Pieter Sonneveld</i>	
12:45-12:57	Dual-targeted CAR T cells	<i>Eric Smith</i>
12:57-1:09	Identifying novel surface Ag targets	<i>Arun Wiita</i>
1:09-1:21	Enhancing responses to T cell directed therapies	<i>Michael Hudecek</i>
1:21-1:33	Targeting fibroblasts to improve T cell therapy	<i>Saad Kenderian</i>
1:33-1:45	Gamma secretase inhibition	<i>Damian Green</i>
1:45-2:15	Discussion	<i>Session faculty + Ivan Borrello</i>
2:15 - 3:00 pm	WORKSHOP ON INFECTION PREVENTION CHAIRS: <i>Nikhil Munshi and Hermann Einsele</i>	
2:15-2:30	Optimizing infection prevention post-CAR T and BsAb therapy	<i>Sarah Hammond</i>
2:30-3:00	Discussion	
3:00 - 3:15 pm	WRAP UP	

Thank you to our sponsors

TITANIUM



PLATINUM



SILVER

